| Drug Name |
Ado-trastuzumab emtansine |
| Drug ID |
BADD_D00046 |
| Description |
Trastuzumab emtansine, formerly called Trastuzumab-DM1 (T-DM1) is a first-in-class HER2 antibody drug conjugate (ADC) comprised of Genentech's trastuzumab antibody linked to ImmunoGen's cell-killing agent, DM1. T-DM1 combines two strategies-- anti-HER2 activity and targeted intracellular delivery of the potent anti-microtubule agent, DM1 (a maytansine derivative)--to produce cell cycle arrest and apoptosis. Trastuzumab emtansine is marketed under the brand name Kadcyla and is indicated for use in HER2-positive, metastatic breast cancer patients who have already used taxane and/or trastuzumab for metastatic disease or had their cancer recur within 6 months of adjuvant treatment. The FDA label has two precautions. First that trastuzumab emtansine and trastuzumab cannot be interchanged. Second that there is a black box warning of serious side effects such as hepatotoxicity, embryo-fetal toxicity, and cardiac toxicity. |
| Indications and Usage |
Not Available |
| Marketing Status |
Prescription |
| ATC Code |
L01FD03 |
| DrugBank ID |
DB05773
|
| KEGG ID |
D09980
|
| MeSH ID |
D000080044
|
| PubChem ID |
Not Available
|
| TTD Drug ID |
Not Available
|
| NDC Product Code |
50242-088; 50242-087; 50242-089 |
| Synonyms |
Ado-Trastuzumab Emtansine | Ado Trastuzumab Emtansine | Trastuzumab Emtansine | Kadcyla | huN901-DM1 | huN901 DM1 | huN901DM1 | Trastuzumab-DM1 Conjugate | Trastuzumab DM1 Conjugate | Trastuzumab-DM1 | Trastuzumab DM1 |
